Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMOK, T.
dc.contributor.authorSCHMID, P.
dc.contributor.authorCASTRO JR., G. de
dc.contributor.authorSYRIGOS, K.
dc.contributor.authorMARTIN, C.
dc.contributor.authorYAMAMOTO, N.
dc.contributor.authorAREN, O.
dc.contributor.authorARRIETA, O.
dc.contributor.authorGOTTFRIED, M.
dc.contributor.authorJAZIEH, A. R.
dc.contributor.authorRAMLAU, R.
dc.contributor.authorTIMCHEVA, C.
dc.contributor.authorTRANI, L.
dc.date.accessioned2017-05-19T14:08:50Z
dc.date.available2017-05-19T14:08:50Z
dc.date.issued2016
dc.description.indexMEDLINE
dc.description.sponsorshipAstraZeneca
dc.identifier.citationANNALS OF ONCOLOGY, v.27, suppl.9, 2016
dc.identifier.eissn1569-8041
dc.identifier.issn0923-7534
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/19827
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofAnnals of Oncology
dc.rightsrestrictedAccess
dc.rights.holderCopyright OXFORD UNIV PRESS
dc.subject.wosOncology
dc.titleGlobal, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE
dc.typeconferenceObject
dc.type.categorymeeting abstract
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryChile
hcfmusp.affiliation.countryJapão
hcfmusp.affiliation.countryArgentina
hcfmusp.affiliation.countryGrécia
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countryChina
hcfmusp.affiliation.countryBulgária
hcfmusp.affiliation.countryPolônia
hcfmusp.affiliation.countryÁrabia Saudita
hcfmusp.affiliation.countryIsrael
hcfmusp.affiliation.countryMéxico
hcfmusp.affiliation.countryisocn
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisogr
hcfmusp.affiliation.countryisoar
hcfmusp.affiliation.countryisojp
hcfmusp.affiliation.countryisocl
hcfmusp.affiliation.countryisomx
hcfmusp.affiliation.countryisoil
hcfmusp.affiliation.countryisosa
hcfmusp.affiliation.countryisopl
hcfmusp.affiliation.countryisobg
hcfmusp.author.externalMOK, T.:Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
hcfmusp.author.externalSCHMID, P.:Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
hcfmusp.author.externalSYRIGOS, K.:Univ Athens, Sotiria Gen Hosp, Dept Internal Med 3, Oncol Unit, Athens, Greece
hcfmusp.author.externalMARTIN, C.:Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina
hcfmusp.author.externalYAMAMOTO, N.:Wakayama Med Univ, Internal Med Resp Med & Med Oncol 3, Wakayama, Japan
hcfmusp.author.externalAREN, O.:CIEC, Dept Oncol, Santiago, Chile
hcfmusp.author.externalARRIETA, O.:Inst Nacl Cancerol INCan, Thorac Oncol Unit, Mexico City, DF, Mexico
hcfmusp.author.externalGOTTFRIED, M.:Meir Med Ctr, Dept Oncol, Kefar Sava, Israel
hcfmusp.author.externalJAZIEH, A. R.:King Saud Univ Hlth Sci Natl Guards Hlth Affairs, Dept Oncol, Riyadh, Saudi Arabia
hcfmusp.author.externalRAMLAU, R.:Poznan Univ Med Sci, Dept Oncol, Poznan, Poland
hcfmusp.author.externalTIMCHEVA, C.:MHAT Womens Hlth, Med Oncol Clin, Sofia, Bulgaria
hcfmusp.author.externalTRANI, L.:AstraZeneca, Global Med Dev, Royston, England
hcfmusp.contributor.author-fmusphcGILBERTO DE CASTRO JUNIOR
hcfmusp.description.issuesuppl 9
hcfmusp.description.volume27
hcfmusp.origemWOS
hcfmusp.origem.wosWOS:000393980600481
hcfmusp.publisher.cityOXFORD
hcfmusp.publisher.countryENGLAND
relation.isAuthorOfPublication0df25c0f-1337-424e-b0f7-41d0fccb51fc
relation.isAuthorOfPublication.latestForDiscovery0df25c0f-1337-424e-b0f7-41d0fccb51fc
Arquivos
Coleções
Comunicações em Eventos - HC/ICESP
Comunicações em Eventos - LIM/24